drugset / Trial / NCT04520620
Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention
Phase 4
Withdrawn
University Hospital of Saint-Etienne
CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang · collab
NaSingle-groupOpen-labelTreatment
Summary
Patients with COVID-19 have special demographic characteristics including thromboembolic risk factors . The pharmacokinetics of enoxaparin administered subcutaneously in the intensive care unit patient are not described. Finally, given the lack of knowledge on the pharmacokinetic/pharmacodynamic properties of enoxaparin in intensive care unit patients infected with SARS-CoV-2, we propose to conduct a prospective multicenter cohort study to collect the biological data necessary for its study.
Timeline
- Start
- 2020-05-02
- Primary completion
- 2020-07-10
- Completion
- 2020-07-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enoxaparin sodium | Other / unclassified | 40 mg | Subcutaneous |
| Subject | Enoxaparin sodium | Other / unclassified | 60 mg | Subcutaneous |
| Subject | Enoxaparin sodium | Other / unclassified | 100 iu/kg | Subcutaneous |
| Subject | Enoxaparin sodium | Other / unclassified | 100 mg | Subcutaneous |